Aberrant expression of interleukin-17A in mast cells contributes to the pathogenesis of hidradenitis suppurativa
British Journal of Dermatology · 16.11.2023 · 189 (6) · 719-729
DOI: 10.1093/bjd/ljad273 ↗Kurz gefasst
Fachartikel in der Zeitschrift British Journal of Dermatology, online erschienen am 04.08.2023. Verfasst von Chia-Bao Chu und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology. Hauptthemen laut MEDLINE: Hidradenitis Suppurativa, Psoriasis. Die Arbeit wurde bisher 17-mal zitiert (Crossref) und nennt 38 Literaturangaben. Gefördert von: Clinical Research Fund of the National Cheng Kung University Medical Center, National Science and Technology Council.
Abstract (Originalsprache)
Background
Hidradenitis suppurativa (HS) significantly diminishes the quality of life for patients. Delayed diagnosis represents a significant challenge in effectively managing HS.
Objectives
To identify and characterize the key mediator in HS.
Methods
Bioinformatic transcriptomic analysis was applied to identify potential candidates contributing to the disease process of HS. Skin samples from 40 patients with HS, four with psoriasis and 29 with normal skin were included. The expression of interleukin (IL)-17A was evaluated and compared among samples of normal skin, psoriatic skin and skin from different stages of HS by immunohistochemistry or dual-colour immunofluorescence. In vitro experiments and RNA sequencing analysis were also conducted to validate the expression of IL-17A and its pathogenic effect in HS.
Results
Transcriptomic database analyses identified IL-17 signalling as a potential contributor to HS. In HS, the predominant IL-17A+ cell population was identified as mast cells. IL-17A+ mast-cell density was significantly elevated in HS, especially in samples with advanced Hurley stages, compared with normal skin and psoriasis samples. The close contact between IL-17A+ mast cells and IL-17 receptor A (IL-17RA)-expressing keratinocytes was demonstrated, along with the significant effects of IL-17A on keratinocyte cell proliferation and HS pathogenic gene expression. Treatment with biologics (brodalumab or adalimumab) reduced the severity of the disease and the number of IL-17A+ mast cells in affected tissues.
Conclusions
The presence of high-density IL-17A+ mast cells may serve as a valuable pathological marker for diagnosing HS. Moreover, developing therapeutic drugs targeting IL-17A+ mast cells may provide a new approach to treating HS.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Dermatology.
- Institute of Basic Medical Sciences.
- International Center for Wound Repair and Regeneration, National Cheng Kung University, Tainan, Taiwan.
- Department of Surgery.
- Center of Cell Therapy, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University, Tainan, Taiwan.
- Department of Physiology, College of Medicine, National Cheng Kung University, Tainan, Taiwan.
ORCID-Profile: Chia-Bao Chu, Chao-Chun Yang, Yuan-Yu Hsueh, Shaw-Jenq Tsai
Förderung
- Clinical Research Fund of the National Cheng Kung University Medical Center
- National Science and Technology Council
Zitieren
APA
Chu, C. B., Yang, C. C., Hsueh, Y. Y., Chen, P. C., Hong, Y. K., Kuo, Y. Y., & Tsai, S. J. (2023). Aberrant expression of interleukin-17A in mast cells contributes to the pathogenesis of hidradenitis suppurativa. British Journal of Dermatology, 189(6), 719-729. https://doi.org/10.1093/bjd/ljad273
Vancouver
Chu CB, Yang CC, Hsueh YY, Chen PC, Hong YK, Kuo YY, et al. Aberrant expression of interleukin-17A in mast cells contributes to the pathogenesis of hidradenitis suppurativa. British Journal of Dermatology. 2023;189(6):719-729. doi:10.1093/bjd/ljad273
BibTeX
@article{Chu2023,
author = {Chu, Chia-Bao and Yang, Chao-Chun and Hsueh, Yuan-Yu and Chen, Po-Chuan and Hong, Yi-Kai and Kuo, Yu-Yun and Tsai, Shaw-Jenq},
title = {Aberrant expression of interleukin-17A in mast cells contributes to the pathogenesis of hidradenitis suppurativa},
journal = {British Journal of Dermatology},
year = {2023},
volume = {189},
number = {6},
pages = {719--729},
doi = {10.1093/bjd/ljad273}
}
EUVIMED